For magnetic resonance imaging (MRI). Sold as Elucirem. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Gadopiclenol (sold as Elucirem), first approved Sep 21, 2022, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Elucirem | Part B | $2.1M | +76% | 62,945 |
| Screening for Brain MetastasesLung Cancer Stage IV, Melanoma Stage IV · University of Zurich | Phase 2 | Not yet recruiting | Mar 25, 2026 |
| Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal DiseaseLeptomeningeal Disease · M.D. Anderson Cancer Center | Not applicable | Recruiting | Feb 17, 2026 |
| Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular DiseaseSteno-occlusive Disease · Guerbet | Phase 3 | Recruiting | Jan 16, 2026 |
| ELUDYN: Assessment of Intra-individual Variability of Vascular Dynamics of Gadopiclenol Injection Parameters in Contrast-enhanced MRIContrast Agent, Medical Imaging Data · Hôpital Fribourgeois | Phase 4 | Active, not recruiting | Jan 16, 2026 |
| Gadopiclenol vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI (Magnetic Resonance Imaging)Contrast Enhanced Images vs. Non-contrast Images, Gadopiclinol Enhanced Images vs. Gadobutrol Enhanced Images · UConn Health | Phase 4 | Recruiting | Feb 26, 2025 |
| Guerbet Liver FibrosisMetabolic Dysfunction-associated Steatotic Liver Disease · Icahn School of Medicine at Mount Sinai | — | Enrolling by invitation | Nov 25, 2024 |
| Gadopiclenol vs Gadoxetate MRI for Liver LesionsLiver Lesion · Icahn School of Medicine at Mount Sinai | — | Enrolling by invitation | Sep 19, 2024 |
| Study of 18F-FFNP Breast PET/MRIBreast Cancer · University of Wisconsin, Madison | Phase 2 | Recruiting | Oct 17, 2023 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
